ProShares Ultra NASDAQ Biotechnology
BIB
BIB
32 hedge funds and large institutions have $54.6M invested in ProShares Ultra NASDAQ Biotechnology in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
11% less funds holding
Funds holding: 36 → 32 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Holders
32
Holding in Top 10
1
Calls
$8.41M
Puts
$8.01M
Top Buyers
| 1 | +$19.9M | |
| 2 | +$18.5M | |
| 3 | +$2.05M | |
| 4 |
OPS
Orion Portfolio Solutions
Omaha,
Nebraska
|
+$1.3M |
| 5 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$548K |
Top Sellers
| 1 | -$1.22M | |
| 2 | -$1.18M | |
| 3 | -$1.06M | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$645K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$259K |